MX2011004549A - Metformin-based ionic co-crystals. - Google Patents

Metformin-based ionic co-crystals.

Info

Publication number
MX2011004549A
MX2011004549A MX2011004549A MX2011004549A MX2011004549A MX 2011004549 A MX2011004549 A MX 2011004549A MX 2011004549 A MX2011004549 A MX 2011004549A MX 2011004549 A MX2011004549 A MX 2011004549A MX 2011004549 A MX2011004549 A MX 2011004549A
Authority
MX
Mexico
Prior art keywords
contra
ionic
crystals
active principles
tablets
Prior art date
Application number
MX2011004549A
Other languages
Spanish (es)
Other versions
MX339374B (en
Inventor
Jose Manuel Francisco Lara Ochoa
Original Assignee
Inst De Investigacion En Quimica Aplic S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst De Investigacion En Quimica Aplic S A De C V filed Critical Inst De Investigacion En Quimica Aplic S A De C V
Priority to MX2011004549A priority Critical patent/MX339374B/en
Priority to PCT/MX2012/000043 priority patent/WO2012148252A2/en
Publication of MX2011004549A publication Critical patent/MX2011004549A/en
Publication of MX339374B publication Critical patent/MX339374B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to two novel metformin-based compounds obtained using the antidiabetic agent glimepiride as a contra-ion in one case and using the antidiabetic agent pioglitazone as a contra-ion in the other case. The resulting spectroscopy, as well as an evaluation of the physicochemical properties thereof, indicate that, in the solid state, both compounds correspond to ionic co-crystals attracted by ionic forces and interactions of the hydrogen bond type. The physicochemical properties of the ionic co-crystals have been shown to have better intrinsic dissolution rates and improved solubilities in relation to those of the precursor contra-ions; properties that can impact favorable on the bioavailability of the novel active principles. Said improved novel active principles are formulated in oral solid pharmaceutical compositions such as tablets or caplets that have advantages over existing commercial tablets. Consequently, tablets containing these novel active principles provide an improved treatment for controlling blood glucose levels in patients with type II diabetes.
MX2011004549A 2011-04-29 2011-04-29 Metformin-based ionic co-crystals. MX339374B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2011004549A MX339374B (en) 2011-04-29 2011-04-29 Metformin-based ionic co-crystals.
PCT/MX2012/000043 WO2012148252A2 (en) 2011-04-29 2012-04-20 Metformin-based ionic co-crystals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2011004549A MX339374B (en) 2011-04-29 2011-04-29 Metformin-based ionic co-crystals.

Publications (2)

Publication Number Publication Date
MX2011004549A true MX2011004549A (en) 2013-01-10
MX339374B MX339374B (en) 2016-05-13

Family

ID=47072969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011004549A MX339374B (en) 2011-04-29 2011-04-29 Metformin-based ionic co-crystals.

Country Status (2)

Country Link
MX (1) MX339374B (en)
WO (1) WO2012148252A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
WO2015042495A2 (en) * 2013-09-22 2015-03-26 Jiva Pharma, Inc. Metformin salts to treat type2 diabetes
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
WO2016069475A1 (en) 2014-10-27 2016-05-06 Aseko, Inc. Subcutaneous outpatient management
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
FR3056908B1 (en) * 2016-09-30 2019-04-19 Nashpharm METFORMIN AND ELAFIBRANOR SALT HAVING DUAL ACTIVITY FOR THE TREATMENT OF OBESITY ASSOCIATED WITH NON-ALCOHOLIC STEATO-HEPATITIS (NASH) AND HYPERTRIGLYCERIDEMIA
CN108299271A (en) * 2018-01-29 2018-07-20 重庆医科大学 A kind of adduct and its preparation and use
CN110357871A (en) * 2019-07-03 2019-10-22 天津大学 Melbine-Pioglitazone salt and its preparation method and application
CN110804017A (en) * 2019-10-31 2020-02-18 天津大学 Salt forming of sulfonylurea compound and metformin, preparation method and application
US20230310462A1 (en) 2020-09-02 2023-10-05 Laboratorios Silanes S.A. De C.V. Combination drug for the control and management of type 2 diabetes mellitus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007183A (en) * 2002-01-25 2006-03-06 Silanes Sa De Cv Lab Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes.
MXPA05009633A (en) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Stable pharmaceutical composition comprising immediate-release glimepiride and delayed-release metformin.
MXPA05014092A (en) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Pharmaceutical compositions containing derivative substances of thiazolidinediones combined with a biguanide for use in type 2 diabetes mellitus.
CN101531657B (en) * 2009-04-23 2013-10-16 重庆医科大学 Dimethyldiguanide of the thiazolidinedione pharmaceutical, preparation method and use thereof
MX2012005998A (en) * 2010-04-13 2013-06-18 Nucitec Sa De Cv Compositions and methods for treating type ii diabetes and related disorders.

Also Published As

Publication number Publication date
MX339374B (en) 2016-05-13
WO2012148252A3 (en) 2012-12-20
WO2012148252A2 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
MX339374B (en) Metformin-based ionic co-crystals.
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
MY149622A (en) Pyrazoles as 11-beta-hsd-1
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
MX2007010532A (en) 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus.
EA026385B9 (en) Fused heterocyclic compounds as ion channel modulators
NO20074872L (en) pyrazoles
WO2011056985A3 (en) Substituted heterocyclic compounds
MX2015003653A (en) Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators.
WO2012117000A8 (en) 3-amino-pyridines as gpbar1 agonists
JO2515B1 (en) Gamma-Crystalline form of ivabradine hydrochloride,a process for its preparation and pharmaceutical composition containing it
MY151295A (en) Pyrimidyl indoline compound
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
MX2009004362A (en) Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk.
MX2011012122A (en) Thiophene derivatives.
MX2009004467A (en) Benzoyl amino heterocyclyl compounds as glucokinase (glk) activators.
MX2009009416A (en) Benzimidazole derivatives and methods of use thereof.
TN2013000413A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
MX2009013501A (en) Piperidine compounds and uses thereof.
WO2011006935A3 (en) Tetrazole derivatives
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
JO2937B1 (en) Peptidic Vasopressin Receptor Agonists
MX360554B (en) Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2.
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration